Comparative Pharmacology
Head-to-head clinical analysis: DEXACORT versus HYDROCORTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXACORT versus HYDROCORTONE.
DEXACORT vs HYDROCORTONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a glucocorticoid receptor agonist that modulates gene expression to produce anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Hydrocortisone is a corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Oral: 0.75-9 mg/day in divided doses; IV: 0.5-9 mg/day every 6-12 hours; IM: 4-20 mg every 2 weeks.
100-500 mg intravenously every 2-6 hours for initial management of adrenal insufficiency; oral maintenance: 20-30 mg daily in divided doses (e.g., 10 mg morning, 5 mg afternoon).
None Documented
None Documented
Plasma terminal elimination half-life is 2.8-3.5 hours in adults, but the biological half-life (duration of HPA axis suppression) is 24-36 hours due to prolonged receptor occupancy
Terminal elimination half-life: 1.5–2.5 hours (plasma), but biological half-life (duration of HPA axis suppression) is 8–12 hours.
Renal (approximately 80% as inactive metabolites, <5% unchanged), biliary/fecal (minor, approximately 15-20%)
Renal (primarily as inactive metabolites; <5% unchanged) and biliary/fecal (minor).
Category C
Category C
Corticosteroid
Corticosteroid